Partners Jennifer Bragg, Avia Dunn and Maya Florence discuss the DOJ’s increasing role in monitoring life science company compliance, both with the FDCA and with respect to compliance program design. This development leads to numerous questions regarding the impact of such oversight, particularly for companies who may find themselves subject to it in the years ahead.
What DOJ Enforcement Shift Means For Life Sciences Cos.
Law360